touchDERMATOLOGY touchDERMATOLOGY
Dermatological disorders, Infectious diseases
Watch Time: 10 mins

Insights from the CAMP-1 and CAMP-2 studies on cantharidin solution (0.7%) in molluscum contagiosum: James Del Rosso

Copy Link
Published Online: Jan 10th 2024

Dr. James Del Rosso (JDR Dermatology Research, Las Vegas, Nevada, USA, and President-Elect American Acne & Rosacea Society) discusses the efficacy and safety results from the CAMP-1 and CAMP-2 studies, highlighting their role in supporting the recent FDA approval cantharidin solution (0.7%) for treatment of molluscum contagiosum. He also examines who benefits most from the cantharidin topical solution and outlines its side effects. Additionally, Dr. Del Rosso explores the impact of FDA approval on clinical practice and the increased availability of this treatment.

Watch the expert perspective interview with Dr James Del Rosso on cantharidin solution (0.7%) drug-device combination and its use in molluscum contagiosum

Questions:

  1. Could you give us a brief overview of the efficacy and safety findings from CAMP-1 and CAMP-2 and how this data supported FDA approval?
  2. Who is likely to benefit most from cantharidin topical solution and what side effects are associated with use?
  3. What will be the impact of FDA approval on clinical practice and how will this increase the availability of treatment?

Disclosures: James Del Rosso is a consultant and speaker for Verrica pharmaceuticals.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Related Videos In Infectious diseases
Infectious diseases
Developed by Touch
Vaccination and the antibiotic landscape of cutaneous sexually transmitted infections: Georg Stary
Watch Time: 5 mins

Dermatology and sexual health raise critical topics such as dermatological manifestations linked to STIs e.g. monkeypox and cutaneous syphilis, the effectiveness of vaccination, and the rise in antibiotic resistance to treat cutaneous STIs.  touchDERMATOLOGY were delighted to speak with Dr Georg Stary (Department of Dermatology, Medical University of Vienna, Vienna, Austria) at EADV 2023 to explore present challenges and future directions in addressing these complex and pressing issues. The abstract ‘Vaccination in STIs: What is the current state?’ (Presentation ID PLB-02) and ‘Antibiotic landscape in genital ulcers’ (Presentation ID D2T12.3B) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions What dermatological manifestations are associated with STIs? How effective are existing vaccines for STIs, and how have recent developments in vaccinations influenced their development? What do you see as the future directions of STI vaccination? What is the present status of antibiotic resistance in STIs? What challenges do healthcare professionals face in selecting appropriate antibiotics for STIs, given the changing microbial landscape? How could a multifaceted approach impact the prevention of antimicrobial resistant STIs? Disclosures: Georg Stary has nothing to disclose in relation to this video interview. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72